Disease Domain | Count |
---|---|
Neoplasms | 4 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Target |
Mechanism PIM1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PIM1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PIM1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date25 Aug 2025 |
Sponsor / Collaborator |
Start Date05 Jun 2025 |
Sponsor / Collaborator |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Erucic acid ( GABA receptor x NF-κB x caspase 3 ) | Seizures More | Preclinical |
Chrysomycin A ( Top II ) | Neoplasms More | Preclinical |
3b(Jouf University) ( PIM1 ) | Neoplasms More | Preclinical |
3a(Jouf University) ( PIM1 ) | Neoplasms More | Preclinical |
8b(Jouf University) ( PIM1 ) | Neoplasms More | Preclinical |